每经AI快讯，有投资者在投资者互动平台提问：请问董秘，贝伐珠欧美销售何时可以开始，有时间表 吗？另外托珠和乌司奴的欧洲销售进程如何？ （记者 张明双） 百奥泰（688177.SH）2月26日在投资者互动平台表示，贝伐珠单抗的欧美销售由合作伙伴主导推进； 托珠单抗与乌司奴单抗在欧洲的商业化工作也在积极筹备中。公司将持续与合作伙伴紧密协作，加速推 进海外市场布局。 ...

Investment Rating - The report does not explicitly provide an investment rating for the rare disease industry. Core Insights - The rare disease sector is characterized by significant policy evolution and market trends, with a focus on the accessibility of treatments and the development of orphan drugs [1][2][5]. Summary by Sections Overview of the Rare Disease Industry - The report analyzes the policies regarding rare diseases in China, the United States, Japan, and Europe, highlighting the differences in definitions and management frameworks across these regions [6][12]. - China has included 207 diseases in its rare disease directory, while the U.S. has no unified directory but manages information through the GARD database [10][11]. Patient Population and Management Status - The report indicates that rare diseases affect over 200 million people globally, with China having more than 20 million affected individuals [12][14]. - The management systems in China are still developing, with significant gaps in data accuracy and epidemiological tracking compared to established systems in the U.S. and Europe [13][14]. Drug Availability and Accessibility - As of 2024, China has approved 55 rare disease drugs, while the U.S. has approved 26, and the EU has approved 15 [15][16]. - The report notes that 70.5% of rare diseases globally have available treatments, but many patients in China still face challenges in accessing these medications due to high costs and limited insurance coverage [16][17]. Leading Companies in Rare Disease Drug Development - The report identifies key players in the rare disease drug development space, emphasizing the growing pipeline of domestic research in China, although it still lags behind international pharmaceutical companies in innovation [16][17].

Core Viewpoint - The company Baotai expects to reduce its net loss for the fiscal year 2025 compared to the previous year, projecting a net profit attributable to the parent company of between -280 million yuan and -390 million yuan, which represents a reduction in loss of between 120.30 million yuan and 230.30 million yuan [1] Group 1 - The reduction in loss is attributed to the company's market expansion efforts [1] - Sales of Adalimumab and Tocilizumab have increased, contributing to the improved financial outlook [1] - The launch of Ustekinumab in the United States has also positively impacted revenue through licensing and sales growth [1]

Core Viewpoint - The company expects to achieve revenue of 900 to 970 million yuan in 2025, indicating an increase of 157 to 227 million yuan compared to the previous year [1] Financial Performance - The net profit attributable to the parent company is projected to be between -280 to -390 million yuan, representing a reduction in losses by 120 to 230 million yuan [1] - The non-GAAP net profit is expected to range from -380 to -490 million yuan, which will decrease losses by 66 to 176 million yuan [1] Market Expansion - The reduction in losses is attributed to the company's market expansion efforts, including increased sales of Adalimumab and Tocilizumab [1] - The launch of Ustekinumab in the United States and growth in licensing and sales revenue also contributed to the improved financial outlook [1]

Group 1: Product Performance and Market Strategy - The patent protection for the injectable form of Esomeprazole will last until after 2035, while the tablet form has faced generic competition in China, yet the company has maintained stable sales growth in the first three quarters of this year due to its strong presence in the gastrointestinal sector [2] - The P-CAB product JP-1366 is expected to participate in the 2027 medical insurance negotiations, with sales anticipated to ramp up significantly after its market entry [2][3] - The domestic sales of P-CAB products reached approximately CNY 1.45 billion in the first three quarters of 2025, representing a year-on-year growth of 65% [3] Group 2: Competitive Landscape in Mental Health Treatments - The average usage rate of long-acting antipsychotic injections in Europe and the U.S. is between 25%-30%, while the rate in China is currently below 1% [3] - The new guidelines for schizophrenia treatment emphasize the importance of long-acting therapies, which is expected to increase the market penetration and sales of the company's long-acting antipsychotic products [3][4] - The company strategically focuses on developing third-generation antipsychotic drugs for long-acting formulations to avoid safety issues associated with first- and second-generation drugs [4] Group 3: Pipeline and Future Developments - The IL-17A/F monoclonal antibody (LZM012) has been submitted for regulatory approval and is expected to participate in the 2027 national medical insurance negotiations [5] - The recombinant human follicle-stimulating hormone (r-FSH) is set to launch in 2026, enhancing the company's product matrix in assisted reproduction [5][6] - The company has significantly reduced losses this year and anticipates entering a product harvest phase with the upcoming launches of r-FSH and LZM012 [6]

Core Viewpoint - 百奥泰 reported a revenue of 684 million yuan for the first three quarters of 2025, representing a year-on-year growth of 17.57%, while the net loss narrowed to 224 million yuan, indicating improved financial performance [1] Group 1: Financial Performance - The company achieved a revenue of 684 million yuan in the first three quarters, marking a 17.57% increase year-on-year [1] - The net loss for the same period was 224 million yuan, showing a reduction in losses compared to the previous year [1] Group 2: Product Development and Approvals - Several products have been approved for sale, including Adalimumab and Tocilizumab in China and other regions, and Bevacizumab in multiple countries [1] - BAT1806 (Tocilizumab) and BAT2206 (Ustekinumab) have been approved in Europe, with sales managed by partners [2][3] - The company is advancing its innovative drug pipeline, with BAT5906 and BAT4406F expected to submit applications for market approval soon [2][3] Group 3: Market Expansion and Strategy - The company is preparing for participation in centralized procurement, optimizing production capacity and supply chain to enhance competitiveness [2] - New guidelines in the EU and the US for biosimilars are expected to lower R&D costs, providing a competitive advantage for the company [2] Group 4: Clinical Trials and Research - BAT6026 is currently in Phase II clinical trials for atopic dermatitis, while BAT8008 is set to begin Phase III trials for cervical cancer and HER2-negative breast cancer in mid-2026 [3] - Ongoing clinical research for BAT8008 in combination with BAT1308 has shown positive efficacy signals, leading to an expansion of the sample size [3] - BAT7111 is in Phase I dose escalation studies, progressing smoothly with three doses explored [3]

Core Insights - IL-6 has emerged as a significant target in autoimmune diseases, with four drugs targeting IL-6/IL-6R approved globally, including tocilizumab, which reached sales of $3.96 billion in 2021 due to its first-mover advantage and multiple indications [1][3] - The expiration of tocilizumab's patent and the entry of biosimilars have intensified competition, prompting pharmaceutical companies to explore new indications beyond rheumatic diseases [3][6] - Recent acquisitions, such as Novartis's $1.4 billion purchase of Tourmaline Bio, indicate a strategic focus on differentiating therapies targeting IL-6 in cardiovascular diseases [4][6] Group 1: IL-6's Role and Market Dynamics - IL-6 is a multifunctional cytokine involved in various physiological and pathological processes, playing a crucial role in inflammation and immune response [2] - The complexity of IL-6's functions makes it challenging to develop drugs that inhibit its harmful effects while preserving its beneficial roles [2][8] - The cardiovascular field is becoming a rapidly advancing area for IL-6 monoclonal antibodies, with Novartis and Novo Nordisk actively pursuing this market [5][7] Group 2: Clinical Developments and Challenges - Novartis's acquisition of Tourmaline Bio was driven by promising Phase II clinical results of pacibekitug, which significantly reduced hs-CRP levels, indicating anti-inflammatory effects [6][8] - The ongoing clinical trials, such as ZEUS, will be critical in validating the efficacy of IL-6 inhibitors in improving hard endpoints like myocardial infarction and stroke [8] - Potential risks associated with long-term IL-6 suppression, including infection and liver toxicity, necessitate careful monitoring in clinical settings [8][9] Group 3: Future Directions and Research - The exploration of IL-6's role in chronic kidney disease and ocular diseases is gaining momentum, with ongoing studies indicating its potential in these areas [9][10] - Innovative approaches, such as dual-targeting antibodies and personalized medicine, are being developed to enhance treatment efficacy for conditions like rheumatoid arthritis [10] - The quest to understand the underlying mechanisms of elevated IL-6 levels and its varied effects across diseases remains a critical area for future research [10]

Core Viewpoint - Baotai Biopharmaceutical Co., Ltd. has received approval from the European Commission for Usymro®, a biosimilar drug for treating moderate to severe plaque psoriasis, active psoriatic arthritis, and moderate to severe active Crohn's disease in adults and children, marking a significant milestone for the company [2][3] Company Overview - Baotai is a global biopharmaceutical company based in Guangzhou, China, focused on developing innovative drugs and biosimilars for various diseases, including cancer and autoimmune disorders [2][3] - The company has successfully launched multiple drugs, including Adalimumab and Tocilizumab, in various markets, establishing itself as a leader in antibody drug development [3] Recent Developments - The approval of Usymro® follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in June 2025, highlighting the company's commitment to advancing its biosimilar pipeline [2] - In October 2024, Baotai signed a licensing and commercialization agreement with Gilead Sciences for BAT2206, another biosimilar, covering markets in the EU, UK, Switzerland, and other regions [2]

Core Viewpoint - The article discusses the extension of centralized procurement to biosimilars in China, highlighting the implications for market dynamics and pricing strategies in the pharmaceutical industry [4][6]. Group 1: Centralized Procurement of Biosimilars - The Anhui Provincial Medical Procurement Platform has initiated information reporting for eight monoclonal antibody products, marking the beginning of centralized procurement for biosimilars [4]. - Biosimilars are large molecule biological products that are similar in quality, safety, and efficacy to already approved reference drugs, and their development is typically more costly and time-consuming than small molecule drugs [4][8]. - The centralized procurement process for biosimilars is expected to take longer than previous chemical drug procurements due to the need for comprehensive data collection and rule formulation [6]. Group 2: Market Impact and Dynamics - The total sales of the eight involved biosimilar products are projected to approach 30 billion yuan in 2024, with specific products like Bevacizumab exceeding 10 billion yuan in sales [9]. - The article emphasizes that the centralized procurement of biosimilars will not drastically disrupt existing market structures but will lead to adjustments within the current competitive landscape [9][10]. - The involvement of multiple companies in the production of these biosimilars indicates a competitive environment, with several products having three or more approved manufacturers [8][9]. Group 3: Characteristics of Biosimilar Procurement - Compared to chemical drug procurement, biosimilar procurement is characterized by smaller price reductions, comprehensive reporting requirements, and a focus on high-quality products [13][14]. - The procurement process aims to clarify market demand and supply, allowing companies to better predict future business conditions and adjust their product pipelines accordingly [6][10]. - The article suggests that the pricing adjustments in biosimilar procurement will be more moderate than those seen in previous chemical drug procurements, reflecting the unique nature of biological products [14][15].

Core Viewpoint - The introduction of centralized procurement for biosimilars in China marks a significant shift in the pharmaceutical industry, aiming to enhance drug accessibility and affordability while maintaining quality standards [1][3][6]. Group 1: Centralized Procurement Overview - The centralized procurement initiative has officially extended to biosimilars, with the Anhui Provincial Medical Procurement Platform issuing a notification for companies to report pricing, sales volume, and production capacity for specific monoclonal antibody products [1][3]. - This marks the first instance of centralized procurement for biosimilars in mainland China, with expectations for a longer timeline for information organization and rule formulation compared to previous chemical drug procurements [1][2]. Group 2: Market Impact and Dynamics - The market for the eight involved biosimilar products is projected to reach nearly 30 billion yuan, with specific products like Bevacizumab exceeding 10 billion yuan in sales [4][6]. - The competitive landscape is expected to be influenced but not drastically altered, as the procurement process aims to provide a clearer understanding of market volumes and guide companies in their operational strategies [2][4]. Group 3: Characteristics of Biosimilar Procurement - Compared to chemical drug procurement, biosimilar procurement is characterized by smaller price reductions, comprehensive reporting requirements, and a focus on high-quality products [7][8]. - The procurement process emphasizes a data-driven approach, requiring companies to report detailed sales figures and product specifications to ensure a thorough understanding of the market [7][9]. Group 4: Future Expectations - The impact of the biosimilar procurement is anticipated to manifest in the performance of related companies and product sales starting from 2026, with ongoing adjustments to market dynamics expected [1][2]. - The overall goal of the procurement initiative is to optimize resource allocation in the pharmaceutical market while ensuring that patient interests remain a priority [5][9].